Updates on Cell & Gene Therapy | Sarawak Society For Cell & Gene Therapy Research (SSCTR)

Venn diagram showing overlap of European regulatory guidance between ATMPs, biosimilars, and other biologics.

Mapping the European Regulatory Overlap in ATMP Guidance

Published on Cytotherapy A recent publication in Cytotherapy reviewed 88 European guidance documents related to advanced therapy...

Regulatory & Compliance

Jun 24

US Health Leaders Urge Smarter Oversight for Cell and Gene Therapies

Published on HHS (LinkedIn) At a recent roundtable on cell and gene therapies, Health Secretary Robert F. Kennedy Jr., FDA Commissioner...

Regulatory & Compliance

Jun 21

Illustration of Malaysia’s biotech policy ecosystem with scientists and government leaders working together in a lab-based setting representing national innovation strategy

Malaysia Unveils National Biotechnology Policy 2.0 to Accelerate Health and Bioeconomy Growth

Published on Ministry of Science, Technology and Innovation (MOSTI) Malaysia has launched the second edition of its National...

Malaysia CGT Updates

Jun 21

Lipid nanoparticles delivering CAR mRNA to CD8 T cells inside a blood vessel, symbolizing in vivo gene delivery and immune reset therapy

In Vivo CAR-T Delivery Achieves Tumor Control and Immune Reset in Preclinical Models

Published on Science Researchers have demonstrated a method for generating CAR T cells inside the body using CD8-targeted lipid...

Educational Insights

Jun 21

Illustration depicting international healthcare leaders and patients working together around a symbolic CAR‑T cell icon, representing the coalition’s mission to expand access

International Coalition Aims to Double CAR‑T Access by 2030

Published on CAR T Vision (via CAR T Vision Coalition website) A new international coalition, CAR T Vision, has launched with a bold...

CGT Milestones

Jun 21

Illustration of stem cell and gene therapy in a high-tech medical setting.

Stem Cell Therapy: Facts, Caution, and Where to Find Trusted Information

In recent years, public interest in stem cell therapy has surged, often fueled by promises of anti-aging, disease reversal, and...

President's Desk

Jun 19

Hospital scene showing clinical staff reviewing liver function data and a gene therapy vial in the foreground, conveying a pause in treatment due to safety concerns

Sarepta Pauses Elevidys for Older Duchenne Patients After Second Liver-Related Death

Published on The Associated Press Sarepta has suspended shipments of Elevidys and paused a trial arm after a second non-ambulatory...

Regulatory & Compliance

Jun 18

Concept image of two biotech companies combining around cardiovascular gene editing technology, symbolizing the acquisition of Verve by Eli Lilly

Eli Lilly Acquires Verve for $1.3B to Boost In Vivo Gene Editing for Heart Disease

Published on Spencer Knight via LinkedIn Eli Lilly has announced plans to acquire Verve Therapeutics in a deal worth up to $1.3 billion....

CGT Milestones

Jun 17

Concept image symbolizing the acquisition of a neuropsychiatry biotech company with a digital brain graphic and two logos merging in a medical tech setting

Supernus Acquires Sage Therapeutics for $795M to Expand Neuropsychiatry Pipeline

Published on Spencer Knight via LinkedIn Supernus Pharmaceuticals is acquiring Sage Therapeutics in a $795 million all-cash deal....

CGT Milestones

Jun 17

Concept image of two biotech companies merging over mRNA cancer therapy research, with symbolic molecular visuals and lab integration themes

BioNTech to Acquire CureVac for $1.25B in All-Stock mRNA Oncology Deal

Published on Spencer Knight via LinkedIn BioNTech has signed a definitive agreement to acquire CureVac in an all-stock transaction valued...

CGT Milestones

Jun 17

Illustration of a biotech research team working on gene therapy for inherited eye disease in a clean modern lab setting in Europe

Barcelona-Based SpliceBio Raises €119M to Target Stargardt Disease

Published on Spencer Knight via LinkedIn SpliceBio has secured €119 million in Series B funding, the largest ever for a biotech in...

CGT Milestones

Jun 17

Photo of a smiling mother recovering in a hospital room with medical staff nearby, symbolizing recovery from advanced melanoma using TIL therapy

Mother of Two Enters Remission After TIL Cell Therapy for Stage 4 Melanoma

Published on Spencer Knight via LinkedIn Missy Christy had already beaten cancer once. Then, as a new mother, she faced it again—this...

CGT Milestones

Jun 17

Concept image of dual-target CAR-T therapy and dendritic cell treatment in a clinical setting, representing progress in glioblastoma cell therapy research

CAR-T and Dendritic Cell Therapies Show Promise in Tackling Glioblastoma

Published on Spencer Knight via LinkedIn Glioblastoma remains one of the deadliest brain cancers with limited treatment options. Two new...

CGT Milestones

Jun 17

Concept image of two pharmaceutical companies merging over molecular designs, symbolizing a strategic immunology acquisition by Sanofi

Sanofi Acquires Blueprint Medicines for $9.1B, Strengthens Rare Immunology Portfolio

Published on Spencer Knight via LinkedIn Sanofi has announced a definitive agreement to acquire Blueprint Medicines in a $9.1 billion...

CGT Milestones

Jun 17

Image of a young woman smiling and active outdoors after recovering from lupus with CAR T-cell therapy, symbolizing restored mobility and remission

Australian CAR T Trial Puts Lupus Into Remission for Young Woman in Historic First

Published on Spencer Knight via LinkedIn Lani Watson, 32, lived with severe lupus that left her in constant pain and unable to walk. In a...

CGT Milestones

Jun 17

Concept image of a business handshake over a 3D brain model, representing a neuroscience acquisition focused on Alzheimer’s and microglial therapy strategy

Sanofi Acquires Vigil Neuroscience for $470M, Expands Alzheimer’s Pipeline

Published on Spencer Knight via LinkedIn Sanofi has agreed to acquire Vigil Neuroscience in a $470 million deal, reinforcing its...

CGT Milestones

Jun 17

https://www.linkedin.com/posts/spencer-knight_genetherapy-cellandgenetherapy-biotech-activity-7330941740536782850-sbMB/?utm_source=share&utm_medium=member_ios&rcm=ACoAAEHdwkIBMc0_k-QYY8yDdD5xx4gDWJ-c8bM

Gene Therapy Frees Patient from 29 Years of Haemophilia B Treatment

Published on Spencer Knight via LinkedIn Elliott Collins, 34, lived with haemophilia B for nearly three decades, relying on frequent...

CGT Milestones

Jun 17

Illustration of siRNA molecules silencing genes inside cells, symbolizing therapeutic breakthroughs in RNA-based treatments across multiple biotech partnerships

2025 Set to Be a Breakout Year for siRNA as Funding and FDA Wins Pile Up

Published on Spencer Knight via LinkedIn siRNA therapies are seeing renewed momentum, with major investments and regulatory wins...

CGT Milestones

Jun 17

Illustration of a baby in a hospital crib surrounded by clinicians and CRISPR research visuals, symbolizing personalized gene-editing therapy for a rare condition

Baby KJ Becomes First Patient to Receive Fully Personalized CRISPR Therapy

Published on Spencer Knight via LinkedIn At just nine months old, KJ was diagnosed with CPS1 deficiency, a rare metabolic disorder...

CGT Milestones

Jun 17

Illustration of biotech firms advancing cell and gene therapy through funding rounds, approvals, and RMAT designations in a dynamic clinical and regulatory landscape

$240M+ in Deals and 1 New Approval Mark CGT Momentum Surge at ASGCT

Published on Spencer Knight via LinkedIn A packed week at ASGCT brought a wave of new CGT developments totaling over $240 million in...

CGT Milestones

Jun 17

4 57 8

Mapping the European Regulatory Overlap in ATMP Guidance

US Health Leaders Urge Smarter Oversight for Cell and Gene Therapies

Malaysia Unveils National Biotechnology Policy 2.0 to Accelerate Health and Bioeconomy Growth

In Vivo CAR-T Delivery Achieves Tumor Control and Immune Reset in Preclinical Models

International Coalition Aims to Double CAR‑T Access by 2030

Stem Cell Therapy: Facts, Caution, and Where to Find Trusted Information

Sarepta Pauses Elevidys for Older Duchenne Patients After Second Liver-Related Death

Eli Lilly Acquires Verve for $1.3B to Boost In Vivo Gene Editing for Heart Disease

Supernus Acquires Sage Therapeutics for $795M to Expand Neuropsychiatry Pipeline

BioNTech to Acquire CureVac for $1.25B in All-Stock mRNA Oncology Deal

Barcelona-Based SpliceBio Raises €119M to Target Stargardt Disease

Mother of Two Enters Remission After TIL Cell Therapy for Stage 4 Melanoma

CAR-T and Dendritic Cell Therapies Show Promise in Tackling Glioblastoma

Sanofi Acquires Blueprint Medicines for $9.1B, Strengthens Rare Immunology Portfolio

Australian CAR T Trial Puts Lupus Into Remission for Young Woman in Historic First

Sanofi Acquires Vigil Neuroscience for $470M, Expands Alzheimer’s Pipeline

Gene Therapy Frees Patient from 29 Years of Haemophilia B Treatment

2025 Set to Be a Breakout Year for siRNA as Funding and FDA Wins Pile Up

Baby KJ Becomes First Patient to Receive Fully Personalized CRISPR Therapy

$240M+ in Deals and 1 New Approval Mark CGT Momentum Surge at ASGCT

Sarawak Society for Cell & Gene Therapy Research

Quick Links